Head-to-head · WeighScore
Effecty vs FitRx
By GLP-1 ScorecardUpdated
Score comparison
Effecty has the higher recorded score — 83.7/100 to 62/100.
Effecty grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. Mid-market pricing offset by brand-name access and LegitScript verification, all 50 states.
We may earn a commission through these links, at no extra cost to you. Commercial relationships affect placement, but never the WeighScore or our editorial findings. See our disclosure.
Factor by factor
These are recorded editorial marks, not a measure of clinical outcomes. Current prices and terms may differ from those used in the marks. See the methodology.
The numbers
Swipe or scroll to compare both providers.
| Metric | Effecty | FitRx |
|---|---|---|
| WeighScore | 83.7/100 | 62/100 |
| Grade | B | C |
| Site position | #21 | #313 |
| Semaglutide | $160/mo | $151/mo (quarterly plan, compounded) |
| Tirzepatide | $240/mo | Not disclosed |
| Coverage | All 50 states | All 50 states |
| Brand-name access | Yes | Yes |
| Oral / sublingual | Not confirmed | Not confirmed |
Site position #21 · B
Strengths
- Brand-name access
- LegitScript-verified, all 50 states
- Both molecules
What to consider
- Higher pricing ($160/$240)
- Injection-only
- Not a value leader
Site position #313 · C
FDAWarning letter issued to FitRX, LLC dba FitRx in February 2026. See the FDA warning-letter database.
Strengths
- Insurance coordination for brand-name GLP-1s — as low as $25/mo
- All four major brand-name GLP-1s available (Ozempic, Wegovy, Zepbound, Mounjaro)
- LegitScript certified
- All 50 states + DC coverage
- Compounded semaglutide from $151/mo quarterly for uninsured patients
What to consider
- Insurance coordination may not work for all plans
- Broader platform (birth control, mental health, hair loss, ED, skincare, primary care)
- Compounded option is semaglutide only — no compounded tirzepatide
- FDA issued FitRX, LLC dba FitRx a warning letter in February 2026; the letter is public in FDA's warning-letter database
Featured provider
CoreAge Rx
CoreAge Rx scores 89.5/100 (B+). Advertises pricing across doses with no membership fee, but starting-price displays and FAQ payment/refund promises need to be reconciled with the selected plan and refund policy.
Commercial relationships affect this placement. The score comparison above is separate.
Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.